Tackling gaps in developing life-changing treatments for dementia

Rui Mauricio¹, Caroline Benn², John Davis³, Gerry Dawson⁴, Lee A Dawson⁵, Alison Evans¹, Nick Fox⁶, John Gallacher⁷, Mike Hutton⁸, John Isaac⁹, Declan N C Jones⁹, Lesley Jones¹⁰, Giovanna Lalli¹¹, Vincenzo Libri¹², Simon Lovestone⁷, Catherine Moody¹³, Wendy Noble¹⁴, Hugh Perry¹⁵, James Pickett¹⁶, David Reynolds¹, Craig Ritchie¹⁷, Jonathan D Rohrer¹⁸, Carol Routledge¹, James Rowe¹⁹, Heather Snyder²⁰, Tara Spires-Jones²¹, Jina Swartz²², Luc Truyen²³, Paul Whiting^{24

25}; Therapeutics for Dementia Consortium

Affiliations

¹ Alzheimer's Research UK, Cambridge, UK.
² Dementia Discovery Fund, London, UK.
³ Alzheimer's Research UK Oxford Drug Discovery Institute, University of Oxford, Oxford, UK.
⁴ P1 Vital, Howbery Business Park, Wallingford, Oxfordshire, UK.
⁵ Cerevance Ltd, Cambridge Science Park, Cambridge, UK.
⁶ Dementia Research Centre, Institute of Neurology, University College London, London, UK.
⁷ Department of Psychiatry, University of Oxford, Oxford, UK.
⁸ Eli Lilly and Company Limited, Surrey, UK.
⁹ Neuroscience External Innovation, Neuroscience Therapeutic Area, Johnson & Johnson Innovation, London, UK.
¹⁰ MRC Centre for Neuropsychiatric Genetics and Genomics, School of Medicine, Cardiff University, Cardiff, Wales, UK.
¹¹ UK Dementia Research Institute, UCL, London, UK.
¹² Institute of Neurology, University College London, London, UK.
¹³ Medical Research Council Head Office, London, UK.
¹⁴ Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
¹⁵ Faculty of Natural and Environmental Sciences, University of Southampton, Southampton, UK.
¹⁶ Alzheimer's Society, London, UK.
¹⁷ Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.
¹⁸ Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK.
¹⁹ Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
²⁰ Alzheimer's Association, Chicago, IL, USA.
²¹ UK Dementia Research Institute, The University of Edinburgh, Edinburgh, UK.
²² European Innovation Hub, Merck Sharp and Dohme, London, UK.
²³ Janssen Research & Development LLC, Titusville, NJ, USA.
²⁴ Dementia Research Institute, UCL, London, UK.
²⁵ ARUK Drug Discovery Institute, Institute of Neurology, University College London, London, UK.

PMID: 31297438
PMCID: PMC6597931
DOI: 10.1016/j.trci.2019.05.001

Review

Tackling gaps in developing life-changing treatments for dementia

Rui Mauricio et al. Alzheimers Dement (N Y). 2019.

. 2019 Jun 24:5:241-253.

doi: 10.1016/j.trci.2019.05.001. eCollection 2019.

Authors

Affiliations

¹ Alzheimer's Research UK, Cambridge, UK.
² Dementia Discovery Fund, London, UK.
³ Alzheimer's Research UK Oxford Drug Discovery Institute, University of Oxford, Oxford, UK.
⁴ P1 Vital, Howbery Business Park, Wallingford, Oxfordshire, UK.
⁵ Cerevance Ltd, Cambridge Science Park, Cambridge, UK.
⁶ Dementia Research Centre, Institute of Neurology, University College London, London, UK.
⁷ Department of Psychiatry, University of Oxford, Oxford, UK.
⁸ Eli Lilly and Company Limited, Surrey, UK.
⁹ Neuroscience External Innovation, Neuroscience Therapeutic Area, Johnson & Johnson Innovation, London, UK.
¹⁰ MRC Centre for Neuropsychiatric Genetics and Genomics, School of Medicine, Cardiff University, Cardiff, Wales, UK.
¹¹ UK Dementia Research Institute, UCL, London, UK.
¹² Institute of Neurology, University College London, London, UK.
¹³ Medical Research Council Head Office, London, UK.
¹⁴ Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
¹⁵ Faculty of Natural and Environmental Sciences, University of Southampton, Southampton, UK.
¹⁶ Alzheimer's Society, London, UK.
¹⁷ Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.
¹⁸ Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK.
¹⁹ Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
²⁰ Alzheimer's Association, Chicago, IL, USA.
²¹ UK Dementia Research Institute, The University of Edinburgh, Edinburgh, UK.
²² European Innovation Hub, Merck Sharp and Dohme, London, UK.
²³ Janssen Research & Development LLC, Titusville, NJ, USA.
²⁴ Dementia Research Institute, UCL, London, UK.
²⁵ ARUK Drug Discovery Institute, Institute of Neurology, University College London, London, UK.

PMID: 31297438
PMCID: PMC6597931
DOI: 10.1016/j.trci.2019.05.001

Abstract

Since the G8 dementia summit in 2013, a number of initiatives have been established with the aim of facilitating the discovery of a disease-modifying treatment for dementia by 2025. This report is a summary of the findings and recommendations of a meeting titled "Tackling gaps in developing life-changing treatments for dementia", hosted by Alzheimer's Research UK in May 2018. The aim of the meeting was to identify, review, and highlight the areas in dementia research that are not currently being addressed by existing initiatives. It reflects the views of leading experts in the field of neurodegeneration research challenged with developing a strategic action plan to address these gaps and make recommendations on how to achieve the G8 dementia summit goals. The plan calls for significant advances in (1) translating newly identified genetic risk factors into a better understanding of the impacted biological processes; (2) enhanced understanding of selective neuronal resilience to inform novel drug targets; (3) facilitating robust and reproducible drug-target validation; (4) appropriate and evidence-based selection of appropriate subjects for proof-of-concept clinical trials; (5) improving approaches to assess drug-target engagement in humans; and (6) innovative approaches in conducting clinical trials if we are able to detect disease 10-15 years earlier than we currently do today.

Keywords: Alzheimer's disease; Clinical trials; Dementia; Diagnosis; Disease-modifying treatment; Earlier detection; Genetic risk factors; Neurodegeneration; Target validation.

PubMed Disclaimer

References

1. Cappa S.F. The Quest for an Alzheimer therapy. Front Neurol. 2018;9:108. - PMC - PubMed
1. Prince M., Comas-Herrera A., Knapp M., Guerchet M., Karagiannidou M. Alzheimer's Disease International (ADI); London: 2016. World Alzheimer Report 2016: Improving Healthcare for People Living with Dementia: Coverage, Quality and Costs Now and in the Future.https://www.alz.co.uk/research/WorldAlzheimerReport2016.pdf Available at:
1. Cummings J., Aisen P.S., DuBois B., Frölich L., Jack C.R., Jones R.W. Drug development in Alzheimer's disease: the path to 2025. Alzheimers Res Ther. 2016;8:39. - PMC - PubMed
1. Agatonovic-Kustrin S., Kettle C., Morton D.W. A molecular approach in drug development for Alzheimer's disease. Biomed Pharmacother. 2018;106:553–565. - PubMed
1. G8 dementia summit: Global action against dementia 11th December 2013. https://www.gov.uk/government/publications/g8-dementia-summit-global-act... Available at:

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Tackling gaps in developing life-changing treatments for dementia

Affiliations

Tackling gaps in developing life-changing treatments for dementia

Authors

Affiliations

Abstract

References

Publication types

Grants and funding

LinkOut - more resources

Full Text Sources